Guardant Health (NASDAQ:GH) Price Target Lowered to $60.00 at Canaccord Genuity Group
Guardant Health (NASDAQ:GH – Get Rating) had its price target dropped by equity research analysts at Canaccord Genuity Group from $65.00 to $60.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity Group’s target price indicates a potential upside of 107.76% from the stock’s previous close.
Other equity analysts have also issued reports about the company. JPMorgan Chase & Co. lowered their target price on Guardant Health from $75.00 to $65.00 and set an “overweight” rating for the company in a report on Friday. Stephens reaffirmed an “overweight” rating